Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.

@article{Rivera2008Phase3S,
  title={Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.},
  author={Edgardo Rivera and Jaime A Mejia and Banu K. Arun and Rosnie B Adinin and Ronald Stewart Walters and Abenaa M. Brewster and Kristine R Broglio and Guosheng Yin and B Esmaeli and Gabriel N Hortobagyi and Vicente Valero},
  journal={Cancer},
  year={2008},
  volume={112 7},
  pages={1455-61}
}
BACKGROUND Previous studies have evaluated 3-week and weekly docetaxel schedules in patients with metastatic breast cancer (MBC). The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and more efficacious. METHODS A phase 3 clinical trial was conducted in patients with MBC who were treated with docetaxel either every 3 weeks or once weekly to determine and compare response rate and duration, time to… CONTINUE READING